What is the appropriate workup for a patient presenting with weakness?

Workup for Weakness

Begin by distinguishing true muscle weakness from subjective fatigue or pain-related motor impairment, then grade the weakness objectively using the Medical Research Council (MRC) Manual Muscle Testing scale, followed by targeted laboratory testing (electrolytes, TSH, creatine kinase) and electrophysiological studies if indicated. 1

Initial Clinical Assessment

Differentiate True Weakness from Mimics

First, confirm you're dealing with actual motor weakness rather than:

• Subjective fatigue or asthenia (different etiologies entirely) 2
• Pain-related motor impairment with preserved strength 1

Objective Strength Grading

Use the MRC Manual Muscle Testing scale to document weakness objectively. An MRC score <80% of maximum (or <48/60 total) defines significant weakness in ICU settings 3. This objective measurement is critical—don't rely on subjective assessment alone.

Pattern Recognition Through History

Determine these key characteristics:

Onset and Progression:

• Acute (hours to days): Consider Guillain-Barré syndrome (GBS), stroke, spinal cord pathology, or toxin exposure 4, 5
• Subacute (days to weeks): Think inflammatory myopathies, endocrine disorders, or medication effects 6
• Chronic: Consider genetic myopathies or motor neuron disease

Distribution Pattern:

• Asymmetric weakness → neurologic conditions (stroke, radiculopathy, mononeuropathy) 1
• Symmetric distal-to-proximal progression → classic GBS presentation 4
• Proximal weakness → myopathies, endocrine disorders 6
• Distal weakness with pain → neuropathies or radiculopathies 1

Associated Features:

• Rapidly progressive bilateral leg/arm weakness without CNS signs → GBS until proven otherwise 4
• Decreased/absent reflexes → peripheral nerve or neuromuscular junction disease 4
• Hyperreflexia or Babinski sign → central nervous system pathology 7
• Dysautonomia (BP/HR instability, pupillary changes) → GBS 4
• Cranial nerve involvement → GBS variants, myasthenia gravis, or brainstem pathology 4, 8

Physical Examination Priorities

Document these specific findings:

• Strength testing: MRC scale in all major muscle groups 3, 1
• Reflex examination: Areflexia vs. hyperreflexia distinguishes peripheral from central causes 4, 7
• Sensory examination: Pattern helps localize lesion
• Cranial nerves: Facial weakness, ophthalmoplegia, bulbar signs 4
• Special signs: Chvostek sign (hypocalcemia), muscle atrophy, fasciculations 1
• Respiratory function: Vital capacity if concerned about neuromuscular respiratory failure 6

Laboratory Workup Algorithm

Tier 1 (Initial Testing for All Patients):

• Electrolytes (sodium, potassium, calcium, magnesium) - electrolyte disturbances are rapidly reversible causes 2, 1
• Thyroid-stimulating hormone (TSH) - endocrine causes are treatable 2, 1
• Creatine kinase (CK) - elevated CK suggests myopathy or rhabdomyolysis; if high, urgent evaluation for rhabdomyolysis 2, 1, 6

Tier 2 (If Tier 1 Normal and Diagnosis Unclear):

• Erythrocyte sedimentation rate (ESR) - inflammatory/rheumatologic conditions 2
• Antinuclear antibody (ANA) - autoimmune myopathies 2
• Complete blood count - infection, malignancy
• Glucose/HbA1c - diabetic neuropathy consideration

Electrophysiological Testing

Electromyography (EMG) and nerve conduction studies (NCS) are indicated when:

• Diagnosis remains unclear after initial workup 2, 1
• Suspecting: GBS, myasthenia gravis, amyotrophic lateral sclerosis, neuropathy, radiculopathy 1
• Differentiating myopathy from neuropathy from neuromuscular junction disease 2

Critical caveat: In ICU patients, EMG/NCS can be performed early (Days 2-10) in uncooperative patients, but the positive predictive value for final weakness diagnosis is only 50%, though negative predictive value is 89% 3. Don't rely solely on early EMG findings.

Neuroimaging

MRI is indicated for:

• Acute presentations suggesting stroke or spinal cord pathology (cauda equina, transverse myelitis, spinal cord infarction) 1, 7
• Focal or asymmetric weakness 1
• Upper motor neuron signs (hyperreflexia, Babinski) 7
• To guide muscle biopsy location 1

Common pitfall: Spinal cord infarction can initially mimic peripheral neuropathy with symmetric weakness—maintain high suspicion if hyperreflexia or spasticity develops, and obtain repeat imaging if clinical picture evolves 7.

Time-Sensitive Diagnoses Requiring Immediate Action

Guillain-Barré Syndrome

If rapidly progressive bilateral weakness with areflexia and no CNS signs:

• Do not delay treatment waiting for confirmatory tests 6
• Maximum disability typically reached within 2 weeks 4
• Treatment options: IV immunoglobulin (0.4 g/kg daily × 5 days) or plasma exchange (200-250 ml/kg × 5 sessions) 4
• Monitor respiratory function closely—respiratory failure is life-threatening complication 6

ICU-Acquired Weakness

In critically ill patients, physical examination with MMT is the primary diagnostic method (used in 84% of studies), followed by EMG/NCS if abnormalities persist 3.

When to Pursue Muscle Biopsy

Consider biopsy when:

• Diagnosis remains unclear after laboratory and electrophysiological testing 2, 1
• Suspected genetic, metabolic, or inflammatory myopathy requiring histologic confirmation 2, 9
• MRI can guide biopsy site selection 1, 9

Special Population Considerations

Geriatric patients: Weakness is associated with poor outcomes; consider frailty and sarcopenia as clinical syndromes, but don't miss treatable causes 1, 10. Minimum laboratory and imaging testing recommended, with neuroimaging if any focal findings 10.

Children <6 years: May present atypically with poorly localized pain, refusal to bear weight, irritability, or unsteady gait rather than clear weakness 4.